CA3142842A1 - Compositions and methods for treating central nervous system disorders - Google Patents
Compositions and methods for treating central nervous system disorders Download PDFInfo
- Publication number
- CA3142842A1 CA3142842A1 CA3142842A CA3142842A CA3142842A1 CA 3142842 A1 CA3142842 A1 CA 3142842A1 CA 3142842 A CA3142842 A CA 3142842A CA 3142842 A CA3142842 A CA 3142842A CA 3142842 A1 CA3142842 A1 CA 3142842A1
- Authority
- CA
- Canada
- Prior art keywords
- suramin
- composition
- less
- patient
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858621P | 2019-06-07 | 2019-06-07 | |
| US62/858,621 | 2019-06-07 | ||
| PCT/US2020/031217 WO2020247127A1 (en) | 2019-06-07 | 2020-05-02 | Compositions and methods for treating central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3142842A1 true CA3142842A1 (en) | 2020-12-10 |
Family
ID=73652889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3142842A Pending CA3142842A1 (en) | 2019-06-07 | 2020-05-02 | Compositions and methods for treating central nervous system disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220226268A1 (enExample) |
| EP (1) | EP3979985A4 (enExample) |
| JP (1) | JP7749169B2 (enExample) |
| CN (1) | CN114340597B (enExample) |
| AU (1) | AU2020288999A1 (enExample) |
| CA (1) | CA3142842A1 (enExample) |
| IL (1) | IL288655A (enExample) |
| WO (1) | WO2020247127A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116867487A (zh) * | 2020-07-29 | 2023-10-10 | 完美日光有限公司 | 苏拉明的制造方法 |
| US20230390226A1 (en) * | 2020-10-22 | 2023-12-07 | Paxmedica, Inc. | Intranasal administration of suramin for treating nervous system disorders |
| IL302224A (en) * | 2020-10-22 | 2023-06-01 | Paxmedica Inc | Administration of anti-purinergic preparations for the treatment of disorders of the nervous system |
| WO2023027994A1 (en) * | 2021-08-23 | 2023-03-02 | Paxmedica, Inc. | Methods for treating nervous system disorders with antipurinergic agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986002266A1 (en) * | 1984-10-12 | 1986-04-24 | United States Of America, Represented By The Unite | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
| AU6527300A (en) * | 1999-08-11 | 2001-03-05 | Josef Pitha | Potentiation of inclusion complex formation of cyclodextrin derivatives |
| US20050063940A1 (en) * | 2002-02-25 | 2005-03-24 | Sveinbjorn Gizurarson | Bioadhesive agent |
| FR2867682B1 (fr) * | 2004-03-22 | 2009-06-05 | Galderma Res & Dev | Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise. |
| EP1802287A2 (en) * | 2004-09-27 | 2007-07-04 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
| AU2007229866A1 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| FR2912591B1 (fr) * | 2007-02-12 | 2009-05-01 | Oberthur Card Syst Sa | Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile. |
| AR062239A1 (es) * | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
| US20120070487A1 (en) * | 2010-03-24 | 2012-03-22 | Aegis Therapeutics Llc | Alkylsaccharide compositions with nutraceuticals |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| FR3025110B1 (fr) | 2014-09-02 | 2016-12-23 | Univ Francois-Rabelais De Tours | Dispositif de pulverisation nasale de produit fluide |
| EP4541420A3 (en) * | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| JP7093559B2 (ja) * | 2016-04-12 | 2022-06-30 | トライジェミナ， インコーポレイテッド | マグネシウム含有オキシトシン製剤および使用の方法 |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| WO2018148262A1 (en) * | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
| CN118697876A (zh) * | 2017-02-09 | 2024-09-27 | 完美日光有限公司 | 用于自闭症谱系障碍药物治疗的方法 |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
-
2020
- 2020-05-02 JP JP2021572548A patent/JP7749169B2/ja active Active
- 2020-05-02 AU AU2020288999A patent/AU2020288999A1/en not_active Abandoned
- 2020-05-02 WO PCT/US2020/031217 patent/WO2020247127A1/en not_active Ceased
- 2020-05-02 EP EP20818146.1A patent/EP3979985A4/en active Pending
- 2020-05-02 CN CN202080055332.3A patent/CN114340597B/zh active Active
- 2020-05-02 US US17/615,673 patent/US20220226268A1/en active Pending
- 2020-05-02 CA CA3142842A patent/CA3142842A1/en active Pending
-
2021
- 2021-12-02 IL IL288655A patent/IL288655A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020288999A1 (en) | 2022-02-03 |
| JP7749169B2 (ja) | 2025-10-06 |
| JP2022535920A (ja) | 2022-08-10 |
| US20220226268A1 (en) | 2022-07-21 |
| CN114340597A (zh) | 2022-04-12 |
| WO2020247127A1 (en) | 2020-12-10 |
| EP3979985A1 (en) | 2022-04-13 |
| IL288655A (en) | 2022-02-01 |
| CN114340597B (zh) | 2025-01-28 |
| EP3979985A4 (en) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220226268A1 (en) | Compositions and methods for treating central nervous system disorders | |
| JP2025087858A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| US20220288096A1 (en) | Compositions and methods for treating an aggregation disease or disorder | |
| KR20250079059A (ko) | 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트 | |
| US20230390223A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
| US20230390226A1 (en) | Intranasal administration of suramin for treating nervous system disorders | |
| US11304947B2 (en) | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | |
| HK40073161B (zh) | 用於治疗中枢神经系统障碍的组合物和方法 | |
| HK40073161A (en) | Compositions and methods for treating central nervous system disorders | |
| US20240277641A1 (en) | Methods for treating nervous system disorders with antipurinergic agents | |
| BR112019018700A2 (pt) | composições farmacêuticas e seus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240409 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250820 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251222 |